Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Greenrose Acquisition Corp. focuses on the specialty and generic drug manufacturing sector, particularly in the U.S. market. The company has faced significant operational challenges, reflected in its declining revenue and stock performance, but maintains a strong gross margin of 59.1%, indicating potential for recovery if operational efficiencies are realized.
Greenrose generates revenue through the production and sale of specialty and generic pharmaceuticals, leveraging its established distribution networks and pricing power in niche markets. Its competitive advantages include a robust product pipeline and strategic partnerships with healthcare providers.
Regulatory approvals for new drug formulations
Changes in healthcare policy affecting drug pricing
Market share shifts in the specialty drug sector
Operational efficiency improvements
Regulatory changes impacting drug approval processes
Technological disruption in drug manufacturing
Increased competition from generic drug manufacturers
Potential entry of large pharmaceutical companies into niche markets
High debt levels relative to equity
Low current ratio indicating potential liquidity issues
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but consumer spending on healthcare can be affected by broader economic conditions.
Higher interest rates may increase financing costs for operational expansions or acquisitions, impacting profitability and valuation multiples.
minimal - The company does not heavily rely on credit for operations, but its high debt/equity ratio indicates some vulnerability.
value - Investors may see potential in the company's recovery and operational improvements.
high - The stock has shown extreme volatility, particularly with a recent 99% decline over three months.
